MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Veracyte Total Assets 2011-2026 | VCYT
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Veracyte
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.41 B | 1.3 B | 1.11 B | 1.16 B | 1.19 B | 457 M | 275 M | 121 M | 78.7 M | 101 M | 75.3 M | 64.8 M | 79.6 M | 19.1 M | 10.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.41 B | 10.5 M | 496 M |
Quarterly Total Assets Veracyte
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 B | 1.34 B | 1.32 B | 1.3 B | 1.28 B | 1.23 B | 1.2 B | 1.11 B | 1.12 B | 1.16 B | 1.16 B | 1.16 B | 1.13 B | - | 1.17 B | 1.19 B | 1.19 B | 1.03 B | 1.03 B | 457 M | 457 M | 457 M | 457 M | 275 M | 275 M | 275 M | 275 M | 121 M | 121 M | 121 M | 121 M | 78.7 M | 78.7 M | 78.7 M | 78.7 M | 101 M | 101 M | 101 M | 101 M | 75.2 M | 75.2 M | 75.2 M | 75.2 M | 64.8 M | 64.8 M | 64.8 M | 64.8 M | 79.6 M | 79.6 M | 79.6 M | 79.6 M | 19.1 M | 19.1 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.37 B | 19.1 M | 510 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 3.52 | -1.26 % | $ 1.05 B |  Canada |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
231 M | $ 3.22 | 2.88 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
62.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 0.8 | 1.81 % | $ 4.36 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
529 M | $ 4.13 | -1.67 % | $ 105 M | Schweiz |
 |
argenx SE
ARGX
|
6.2 B | $ 709.52 | 0.88 % | $ 25 B |  Niderland |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.4 | -5.82 % | $ 8.18 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
1.3 B | $ 228.5 | -1.09 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
315 M | $ 6.1 | 0.83 % | $ 497 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
271 M | $ 6.6 | -0.45 % | $ 181 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
271 M | $ 14.52 | 1.11 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioCardia
BCDA
|
2.99 M | $ 1.3 | 2.36 % | $ 27.5 M | USA |
 |
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
105 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.67 | 1.14 % | $ 16.8 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.49 | -1.32 % | $ 380 M | Britain |
 |
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 92.62 | 2.3 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 8.28 | 2.73 % | $ 1.35 B | Britain |
 |
AstraZeneca PLC
AZN
|
114 B | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
76.9 M | $ 1.16 | 4.5 % | $ 34.9 M | USA |